Key Points

  • 1. Novavax's updated COVID-19 vaccine receives emergency use authorization in Taiwan, making it widely available for individuals aged 12 and older.
  • 2. The vaccine has demonstrated the ability to induce immune responses against various COVID-19 variants and stimulate both arms of the immune system.
  • 3. Common side effects of the vaccine include headache, nausea, muscle and joint pain, injection site tenderness, fatigue, and malaise.
  • 4. The vaccine has also received authorization in the U.S., the European Union, Canada, and from the World Health Organization.
  • 5. It is important to discuss any medical conditions or allergies with a vaccination provider before receiving the Novavax COVID-19 Vaccine.

Novavax, Inc. (Nasdaq: NVAX), a global leader in protein-based vaccines, has attained a significant milestone as its updated COVID-19 vaccine, Nuvaxovid™ XBB.1.5 dispersion for injection, received Emergency Use Authorization (EUA) from the Taiwan Food and Drug Administration. This approval marks a pivotal step forward in combating the ongoing pandemic and extends the preventive measure to individuals aged 12 and older.

The Authorization

The authorization follows rigorous evaluations of non-clinical data, demonstrating that Novavax's updated vaccine induces robust immune responses against several variants, including XBB.1.5, XBB.1.16, and XBB.2.3. Notably, the vaccine exhibits compelling neutralizing antibody responses against subvariants BA.2.86, EG.5.1, FL.1.5.1, and XBB.1.16.6, along with eliciting CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6.

"Receiving Emergency Use Authorization in Taiwan underscores the efficacy of our protein-based non-mRNA vaccine against diverse COVID-19 variants," affirmed John C. Jacobs, President and CEO of Novavax. "The authorization reflects our commitment to supporting global vaccination efforts."

Despite this achievement, concerns surrounding potential revenue risks have prompted a downgrade in the company's stock rating. MoffettNathanson, in a recent report, downgraded Novavax's shares from Neutral to Sell, citing an overvaluation concern. Analysts raised apprehensions about the sustainability of revenue streams amid steep stock price hikes.

"In light of the limited financial disclosures by the company, investors may not fully comprehend the formidable revenue challenges facing Novavax in fiscal year 2024," noted analysts at MoffettNathanson.

The decline in stock recommendation primarily stems from concerns about revenue sources, with recent growth primarily driven by content distribution payments linked to a new significant client and substantial price hikes for subscription-based video-on-demand (SVOD) services. However, reports from Antenna revealed a slowdown in the growth rate of premium SVOD subscriptions in the U.S., signaling potential market constraints.

It is important to note that the trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration (FDA). The Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) has not been licensed by the FDA but has been authorized for emergency use to prevent COVID-19 in individuals aged 12 and older.

While Novavax's updated COVID-19 vaccine garners increased global acceptance, concerns about revenue sustainability continue to impact market sentiment, urging investors to reevaluate the long-term financial outlook for the company.

Disclaimer: The article is for informational purposes only and doesn't constitute financial advice. Readers are encouraged to perform due diligence and consult financial experts before making investment decisions.



About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $322M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX